Johnson & Johnson Elmiron — Product liability contingency, number of claimants decreased by 12.0% to $810.00 in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 62.7%, from $2.17K to $810.00. This is a positive signal — lower values indicate better performance for this metric.
An increase in the number of claimants suggests escalating legal risk and potential future financial liabilities, while a decrease may indicate that the litigation is reaching a resolution or that new claims are slowing.
This metric represents the total count of active legal claims filed against the company regarding the pharmaceutical pro...
Comparable to mass tort litigation counts for specific pharmaceutical products at other large-cap healthcare companies, often evaluated alongside legal reserve provisions.
jnj_segment_elmiron_product_liability_contingency_number_of_claimants| Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.30K | $2.00K | $2.07K | $2.15K | $2.15K | $2.15K | $2.17K | $2.17K | $2.17K | $1.14K | $920.00 | $810.00 |
| QoQ Change | — | +53.8% | +3.5% | +3.9% | +0.0% | +0.0% | +0.9% | +0.0% | +0.0% | -47.5% | -19.3% | -12.0% |
| YoY Change | — | — | — | +65.4% | +7.5% | — | +4.8% | +0.9% | +0.9% | -47.0% | -57.6% | -62.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.